[Form 3] SOPHiA GENETICS SA Initial Statement of Beneficial Ownership

SOPHiA GENETICS SA Chief Executive Officer Camblong Jurgi has filed a Form 3 reporting his initial ownership in the company.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Executive Officer Camblong Jurgi has filed a Form 3 reporting his initial ownership in the company. He directly holds 3,307,325 ordinary shares, including 616,351 ordinary shares issuable upon settlement of restricted stock units that vest over time, and 891,320 ordinary shares have been pledged under lending arrangements. He also reports several share options giving rights to buy additional ordinary shares at exercise prices ranging from 3.1600 to 18.0000 per share, with expirations between late 2028 and early 2035. Certain option and RSU awards vest in scheduled monthly or quarterly installments through 2028.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Camblong Jurgi

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 4,112,733 contracts (Direct); Ordinary Shares — 3,307,325 shares (Direct)

Footnotes (6)

1. F1. Includes 616,351 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 19,938 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 223,215 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 145,575 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 227,623 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
2. F2. 891,320 ordinary shares have been pledged pursuant to lending arrangements.
3. F3. The share options are fully vested and exercisable.
4. F4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
5. F5. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
6. F6. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Camblong Jurgi report owning in SOPH on this Form 3?

Camblong Jurgi reports direct ownership of 3,307,325 SOPHiA GENETICS ordinary shares. This total includes 616,351 shares issuable upon vesting of restricted stock units and shares that have been pledged under lending arrangements.

How many SOPHiA GENETICS RSU-based shares does the CEO report on Form 3 for SOPH?

The CEO reports 616,351 SOPHiA GENETICS ordinary shares issuable upon settlement of four restricted stock unit grants. These RSUs vest in monthly or quarterly installments between May 2026 and April 2028, subject to his continued service with the company.

Are any of Camblong Jurgi’s SOPH shares pledged as collateral?

Yes. The filing notes that 891,320 SOPHiA GENETICS ordinary shares have been pledged under lending arrangements. Pledged shares remain owned by the holder but serve as collateral for borrowing, which can introduce additional financial obligations tied to the stake.

What stock options does the SOPHiA GENETICS CEO report holding on Form 3?

Camblong Jurgi reports multiple share options to buy SOPHiA GENETICS ordinary shares. These options have exercise prices ranging from 3.1600 to 18.0000 per share and expiration dates from November 2028 through April 2035, with some already fully vested and others vesting over time.

How do the CEO’s SOPH restricted stock units vest over time?

The Form 3 footnotes describe four RSU grants vesting monthly or quarterly through April 2, 2028. One grant also has 50% vesting on April 2, 2026, with the remaining units vesting in equal quarterly installments through April 2, 2027, conditioned on continued service.

Does this SOPHiA GENETICS Form 3 show any insider buying or selling of SOPH shares?

No insider buying or selling transactions are shown in this Form 3. The entries are categorized as holdings, detailing existing ordinary share ownership, pledged shares, restricted stock units, and outstanding share options rather than new market purchases or sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:46 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3,307,325(1)(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(3)	11/29/2028	Ordinary Shares	100,000	$3.16	D
Share Option (Right to Buy)	(3)	11/26/2029	Ordinary Shares	29,000	$4.01	D
Share Option (Right to Buy)	(3)	06/11/2030	Ordinary Shares	181,500	$4.24	D
Share Option (Right to Buy)	(3)	07/22/2031	Ordinary Shares	556,604	$18	D
Share Option (Right to Buy)	(4)	04/03/2033	Ordinary Shares	1,096,654	$4.72	D
Share Option (Right to Buy)	(5)	04/02/2034	Ordinary Shares	1,143,293	$4.96	D
Share Option (Right to Buy)	(6)	04/02/2035	Ordinary Shares	1,005,682	$3.29	D

Explanation of Responses:

1. Includes 616,351 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 19,938 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 223,215 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 145,575 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 227,623 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.

2. 891,320 ordinary shares have been pledged pursuant to lending arrangements.

3. The share options are fully vested and exercisable.

4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.

5. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.

6. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)